Suppr超能文献

地中海贫血患者的生长、青春期发育及其管理

Growth and puberty and its management in thalassaemia.

作者信息

De Sanctis V

机构信息

Department of Growth and Reproduction, Pediatric and Adolescent Unit, Arcispedale S. Anna, Ferrara, Italy.

出版信息

Horm Res. 2002;58 Suppl 1:72-9. doi: 10.1159/000064766.

Abstract

The purpose of this review is to report the personal experience on growth and pubertal development in a large number of thalassaemic and ex-thalassaemic patients followed at the Pediatric and Adolescent Unit of Ferrara. Secondary amenorrhoea (SA), hypogonadism and short stature are the commonest endocrine and auxological complications. The anterior pituitary gland is particularly sensitive to free radical oxidative stresses and exposure to this. Magnetic resonance imaging (MRI) shows that even a modest amount of iron deposition within the anterior pituitary can interfere with its function. Other possible cause of hypogonadism in beta-thalassaemia major include liver disorders, chronic hypoxia, diabetes mellitus and zinc deficiency. The treatment of pubertal disorders consists of hormone replacement therapy with sex steroids. Successful induction of spermatogenesis and ovulation has been reported after hormonal stimulation with gonadotrophins. Height above the 10th centile was achieved in 50% of males and 64% of females. Eight prepubertal thalassaemic patients, 6 males and 2 females, ranging in age from 8.6 to 11.7 years, were treated with GH. After the first 12 months of GH treatment a significant increase of growth velocity was observed in 6 patients who doubled growth velocity before basal value (4 cm or more above the basal value), 2 patients had a partial response (2-4 cm above the basal value). In the following 3 years all thalassaemic patients had a partial response to the treatment with GH. These data indicate that despite somewhat reduced sensitivity to GH, compared to GH deficiency children, there is evidence indicating that thalassaemic patients may benefit from GH treatment. Sixty-eight thalassaemic patients (30 males and 38 females) who had successfully undergone bone marrow transplantation (BMT) during childhood were studied. Following BMT growth rate decelerated when compared to Tanner and Whitehouse standards. Twenty-nine ex-thalassaemics reached final height. The patterns of growth during puberty was variable in ex-thalassaemic males, while in all but 3 ex-thalassaemic females we observed an improvement in the percentile of standing height. A gonadal dysfunction was found in 68% of ex-thalassaemic patients. Since the quality of life of these patients is an important aim, it is vital to monitor carefully the growth and pubertal development in order to detect abnormalities and to initiate appropriate and early treatment.

摘要

本综述的目的是报告在费拉拉儿科和青少年科随访的大量地中海贫血和曾患地中海贫血患者的生长及青春期发育的个人经验。继发性闭经(SA)、性腺功能减退和身材矮小是最常见的内分泌和体格方面的并发症。垂体前叶对自由基氧化应激及其暴露尤为敏感。磁共振成像(MRI)显示,即使垂体前叶内有少量铁沉积也会干扰其功能。重型β地中海贫血中性腺功能减退的其他可能原因包括肝脏疾病、慢性缺氧、糖尿病和锌缺乏。青春期疾病的治疗包括用性激素进行激素替代疗法。据报道,用促性腺激素进行激素刺激后,成功诱导了精子发生和排卵。50%的男性和64%的女性身高达到第10百分位以上。8名青春期前的地中海贫血患者,6名男性和2名女性,年龄在8.6至11.7岁之间,接受了生长激素(GH)治疗。在GH治疗的前12个月后,6名患者的生长速度显著增加,其生长速度在基础值之前翻倍(比基础值高4厘米或更多),2名患者有部分反应(比基础值高2 - 4厘米)。在接下来的3年里,所有地中海贫血患者对GH治疗都有部分反应。这些数据表明,尽管与生长激素缺乏症儿童相比,地中海贫血患者对GH的敏感性有所降低,但有证据表明地中海贫血患者可能从GH治疗中获益。对68名在儿童期成功接受骨髓移植(BMT)的地中海贫血患者(30名男性和38名女性)进行了研究。与坦纳和怀特豪斯标准相比,BMT后生长速度减慢。29名曾患地中海贫血者达到最终身高。曾患地中海贫血男性青春期的生长模式各不相同,而在除3名以外的所有曾患地中海贫血女性中,我们观察到站立身高百分位数有所改善。在68%的曾患地中海贫血患者中发现性腺功能障碍。由于这些患者的生活质量是一个重要目标,仔细监测生长和青春期发育以发现异常并启动适当的早期治疗至关重要。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验